The two highest-ranking leaders within the FDA’s Office of Prescription Drug Promotion (OPDP) have stepped down, according to ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

For a second time in less than a month, a new CDMO has uncloaked.  | For a second time in less than a month, a new CDMO has ...

The FDA has sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...

When Phathom Pharmaceuticals launched its first direct-to-consumer ads for Voquezn | In a commercial debuting Monday, Kenan ...

Particulate contamination has sparked the recalls of numerous injectable drugs over the years, with Amneal’s hospital med ...

Pharma brands spend billions annually trying to engage healthcare providers (HCPs), yet much of this outreach has a limited ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

An investigation into the national security implications of pharma imports has been underway for two weeks, the Trump ...

As tariff threats and FDA staff cuts thrust the biopharma world into uncharted waters, President Donald Trump is offering the ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...